Description | The human antibody 54042-4 shows potent neutralization against authentic SARS-CoV-2 viruses, including variants of concern (VOCs). 54042-4 has high affinity with the apex of the RBD and exhibited potent SARS-CoV-2 neutralization against USA-WA1, Alpha, Beta, Gamma, and Delta VOCs. |
Clonality | Monoclonal |
Host Species | Human |
Target Species | SARS-CoV-2 (USA-WA1, Alpha, Beta, Gamma and Delta) |
Epitope | Overlapping the binding sites of ACE2 to SARS-CoV-2 S protein. |
Affinity | 21.8 nM |
Expression Species | HEK293F or CHO cell line |
Conjugation | Unconjugated |
Purity | >95% |
Endotoxin | <1 EU/mg |
Form | Liquid |
Purification | Protein A purified |
Sterility | 0.2 μM filtered |
Formulation | PBS, pH 7.4 |
Preservation | No preservatives |
Stabilizer | No stabilizers |
Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
Application | ELISA; BLI; Neut |
Application Notes | ELISA: The antibody started at 10 μg/mL with a serial 1:5 dilution. Bio-layer interferometry (BLI): The KD of 54042-4 binding to SARS-CoV-2 RBD is 21.8 nM. Neutralization assay: 54042-4 neutralized each virus (USA-WA1, Alpha, and Beta, Gamma and Delta) potently with IC50 values of 3.2, 5.5, 9.7, 3.7, and 1.5, and IC80 values of 10, 48, 49, 11.4, and 3.9 ng/mL, respectively. |
ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
WB | Western Blot Protocol |
FC | Flow Cytometry Protocol |
Target | SARS-CoV-2 S1 |
Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
Research Area | Coronavirus Disease 2019 |
Related Disease | Coronavirus Disease 2019 |